ArticleFrontiers in endocrinology2026
Differences in management and outcomes between pheochromocytomas and sympathetic paragangliomas.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The primary aim was to study the differences between pheochromocytomas (PCC) and sympathetic paragangliomas (PGL) in management and short- and long-term outcomes. Methods: This was a retrospective study of 220 patients that had undergone surgery for PCC or PGL and had been managed during the period 2005-2025 at the Department of Endocrinology, Karolinska University Hospital. Patient data were collected from electronic medical journals. Results: Patients with PCC compared to PGL had a longer duration of preoperative treatment with alpha-adrenergic receptor antagonist (50.0 vs. 34.0 days, Conclusions: There are many similarities between PCC and PGL; however, patients with PGL had a somewhat worse prognosis regarding short- and long-term outcomes, including longer length of stay at the hospital, risk for new associated tumors, and less positive effects on dysglycemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.